Subscribe

Eurobio Scientific S.A. (ALERS.PA)

EUR21.40 +0.00 (+0.00%)
FR PAR Healthcare Medical - Devices
Address 7 avenue de Scandinavie 91953
Les Ulis, FR
CEO Denis Fortier
Website eurobioscientific.com
IPO 2005-11-18
ISIN FR0013240934

Explore sections of this company profile

Description

Eurobio Scientific S.A. specializes in the conceptualization, development, and distribution of sophisticated diagnostic products. Its key therapeutic and research domains include transplantation, infectious illnesses, life sciences, and oncology. The company's portfolio features the Tetanus Quick Stick, an essential emergency diagnostic for rapidly determining a patient's tetanus vaccination status. It also distributes cell culture media, molecular biology reagents, and proprietary antibody solutions. Proprietary developments from Eurobio Scientific encompass the BJI InoPlex, a multiplex serological test for diagnosing prosthetic joint infections, and the EBX-044 PCR test, utilized for identifying SARS-CoV-2 variants. Its licensed offerings include AlloMap, a gene-expression profiling blood test designed for the ongoing surveillance of heart transplant recipients. The firm, initially named Diaxonhit, changed its corporate identity to Eurobio Scientific S.A. in June 2018. Founded in 1997, the company is headquartered in Les Ulis, France.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
EUR21.40 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.6K
Beta
0.72
Float Shares
3.03M
Free Float %
30.1%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
-0.46% +1.40% -4.80% -7.23% -10.29% -10.47% -12.80% +28.24% +12.26% +165.85% -78.11%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
21.40
DCF (Unlevered) 48.18 +125.2%
DCF (Levered) 79.84 +273.1%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 100% Bullish
Rating 2026-05 Change
Strong Buy 0 0
Buy 1 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
Altman Z-Score
4.52
Safe zone
Piotroski F-Score
6 / 9
Average
MOAT Score
3 / 10
No MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
3 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
4 / 5
High
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Medical - Devices: +11.2%
    +9.1% Q4'25: +22.8% (vs Q4'23)
  • ✓
    EPS growth Medical - Devices: +28.5%
    +23.1% Q4'25: +9.1% (vs Q4'23)
  • ✓
    FCF margin FCF growth · Medical - Devices: +30.9%
    +0.5% Q4'25: +2.0% (vs Q4'23)
  • ✗
    EBIT margin Medical - Devices: +6.2%
    +6.4% ★ Q4'25: +8.6% (vs Q4'23)
  • ✗
    ROIC Medical - Devices: +3.3%
    +3.8% ★ Q4'25: +10.7% (vs Q4'23)
  • ✗
    Share dilution Medical - Devices: 0.0%
    +0.0% ★ Q4'25: -2.7% (vs Q4'23)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×
    0.81× Q4'25: 0.44× (vs Q4'23)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.72) × ERP
WACC = 93% × Ke + 7% × Kd (18.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 48.18 Current price: 21.40
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2006
actual 		Dec 2008
actual 		Dec 2009
actual 		Dec 2010
actual 		Dec 2012
actual 		Dec 2013
actual 		Dec 2014
actual 		Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
1 Rev. Ana.
1 EPS Ana.
Revenue
7.10M
est.
4.22M
est: 7.10M (-40.6%)
4.89M
est: 5.07M (-3.6%)
8.42M
est: 8.12M (+3.7%)
5.39M
est: 5.07M (+6.1%)
31.22M
est: 31.53M (-1.0%)
31.04M
est: 31.26M (-0.7%)
29.78M
est: 29.80M (-0.1%)
27.83M
est: 27.48M (+1.2%)
42.78M
est: 48.30M (-11.4%)
51.07M
est: 50.60M (+0.9%)
59.48M
est: 59.10M (+0.6%)
188.86M
est: 188.90M (0.0%)
184.71M
est: 184.10M (+0.3%)
152.61M
est: 152.50M (+0.1%)
130.65M
est: 130.60M (+0.0%)
154.95M
est: 138.00M (+12.3%)
169.00M
est: 168.40M (+0.4%)
175.90M
175.90M – 175.90M
+4.5% YoY
EBITDA
2.11M
est.
-10.93M
est: 2.07M (-628.6%)
-8.90M
est: 1.48M (-702.4%)
-6.27M
est: -14.02M (+55.3%)
-6.38M
est: -8.76M (+27.2%)
-4.66M
est: -40.20M (+88.4%)
-3.36M
est: -4.89M (+31.2%)
-4.30M
est: -4.63M (+7.3%)
-4.95M
est: -2.38M (-107.9%)
-2.58M
est: -10.73M (+76.0%)
4.35M
est: -5.12M (+184.8%)
6.94M
est: 2.48M (+179.6%)
88.57M
est: 13.13M (+574.8%)
79.63M
est: 10.44M (+663.1%)
40.49M
est: 9.66M (+319.1%)
24.55M
est: 8.20M (+199.2%)
20.40M
est: 31.26M (-34.7%)
19.70M
est: 38.14M (-48.4%)
39.84M
39.84M – 39.84M
+4.5% YoY
EBIT
1.69M
est.
-11.40M
est: 1.65M (-788.6%)
-9.66M
est: -8.14M (-18.7%)
-6.97M
est: -15.46M (+54.9%)
-6.67M
est: -9.66M (+31.0%)
-7.06M
est: -40.69M (+82.7%)
-5.69M
est: -6.99M (+18.6%)
-6.09M
est: -5.60M (-8.6%)
-7.45M
est: -7.93M (+6.1%)
-8.60M
est: -13.05M (+34.1%)
-1.16M
est: -7.97M (+85.5%)
569.0K
est: -1.77M (+132.2%)
81.21M
est: 158.6K (+51,116.9%)
71.77M
est: 126.1K (+56,829.0%)
30.97M
est: 116.7K (+26,433.3%)
11.33M
est: 99.1K (+11,336.2%)
12.00M
est: 22.63M (-47.0%)
10.80M
est: 27.62M (-60.9%)
28.85M
28.85M – 28.85M
+4.5% YoY
Net Income
-21.11M
est.
-8.93M
est: -64.49M (+86.2%)
-7.70M
est: -66.57M (+88.4%)
-7.75M
est: -37.45M (+79.3%)
-5.77M
est: -7.70M (+25.1%)
-5.99M
est: -35.85M (+83.3%)
-5.49M
est: -5.94M (+7.6%)
-5.88M
est: -5.31M (-10.8%)
-7.73M
est: -5.68M (-36.1%)
-9.97M
est: -12.86M (+22.5%)
-2.77M
est: -10.53M (+73.7%)
3.15M
est: -3.22M (+198.0%)
73.48M
est: 6.10M (+1,105.2%)
60.54M
est: 4.85M (+1,149.0%)
24.94M
est: 4.49M (+455.6%)
4.84M
est: 3.81M (+26.9%)
4.00M
est: 9.02M (-55.6%)
4.90M
est: 7.99M (-38.7%)
11.58M
11.58M – 11.58M
+44.9% YoY
SGA
1.43M
est.
5.74M
est: 1.40M (+309.8%)
5.57M
est: 4.10M (+35.8%)
6.91M
est: 1.63M (+323.5%)
4.43M
est: 1.02M (+334.2%)
14.43M
est: 27.52M (-47.6%)
14.03M
est: 12.98M (+8.1%)
13.14M
est: 12.33M (+6.5%)
12.50M
est: 11.45M (+9.1%)
16.93M
est: 18.65M (-9.3%)
15.96M
est: 15.13M (+5.5%)
14.94M
est: 16.27M (-8.2%)
22.50M
est: 25.10M (-10.4%)
24.50M
est: 19.96M (+22.8%)
31.00M
est: 18.48M (+67.8%)
33.52M
est: 15.69M (+113.7%)
45.46M
est: 33.10M (+37.3%)
53.00M
est: 40.39M (+31.2%)
42.19M
42.19M – 42.19M
+4.5% YoY
EPS
-2.06
est.
-6.67
est: -6.39 (-4.4%)
-5.47
est: -6.59 (+17.0%)
-4.68
est: -3.71 (-26.2%)
-3.21
est: -5.34 (+39.8%)
-2.11
est: -2.67 (+20.9%)
-1.77
est: -1.44 (-22.7%)
-1.66
est: -1.68 (+1.4%)
-1.98
est: -1.90 (-4.3%)
-1.14
est: -0.44 (-159.1%)
-0.28
est: 0.03 (-1,033.3%)
0.29
est: 0.22 (+31.8%)
6.56
est: 6.30 (+4.2%)
5.58
est: 5.81 (-4.0%)
2.20
est: 2.46 (-10.6%)
0.43
est: 0.43 (+0.0%)
0.39
est: 0.88 (-55.7%)
0.48
est: 0.78 (-38.5%)
1.13
1.13 – 1.13
+44.9% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-28 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-27 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-26 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-25 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-22 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-21 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-20 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-19 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-18 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-15 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-14 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-13 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-12 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-11 A- 4/5 5/5 3/5 4/5 3/5 1/5 4/5
2026-05-08 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-07 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-06 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-05 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-05-04 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-30 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-29 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-28 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-27 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-24 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-23 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-22 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-21 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-20 C 2/5 5/5 1/5 1/5 1/5 1/5 1/5
2026-04-17 B+ 3/5 5/5 2/5 4/5 2/5 1/5 4/5
2026-04-16 B+ 3/5 5/5 2/5 4/5 2/5 1/5 4/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
22.43M
OE per share TTM
2.14
Owner's Yield
9.87%
Maintenance CapEx ratio
388.42%
Maint CapEx / Avg PPE
7.5%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock

This company is not held by any ETF in our universe.

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
32.8K
Shares Outstanding
10.07M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Denis Fortier Chief Executive Officer & Chairman 700.0K male
Olivier Bosc Deputy Chief Executive Officer & Chief Financial Officer 243.0K male
Cathie Marsais Deputy Chief Executive Officer, Chief Operating Officer, Operations, Affairs Quality & Regulatory 194.0K female
Jean-Michel Carle Grandmougin Deputy GM, Business Developer & Director 120.0K male
Hanneke Merkens CMO, COM and Manager of International Product, Infectious & Transplant — female
Maarten Penning Chief Technology Officer and Director of R&D — male
Eric Pryjda Vice President of Sales & Marketing — male
Thomas Iff Chief Business Officer — male
Thomas Moreaux CHRO & Ressources Humaines — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Medical - Devices